Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders.
Köhrer S, Dittrich T, Schorb M, Weinhold N, Haberbosch I, Börmel M, Pajor G, Goldschmidt H, Müller-Tidow C, Raab MS, John L, Seckinger A, Brobeil A, Dreger P, Tornóczky T, Pajor L, Hegenbart U, Schönland SO, Schwab Y, Krämer A. Köhrer S, et al. Among authors: haberbosch i. Leukemia. 2023 Dec;37(12):2468-2478. doi: 10.1038/s41375-023-02056-y. Epub 2023 Oct 11. Leukemia. 2023. PMID: 37821581 Free PMC article.
A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed/refractory multiple myeloma.
Dittrich T, Köhrer S, Schorb M, Haberbosch I, Börmel M, Goldschmidt H, Pajor G, Müller-Tidow C, Raab MS, Hegenbart U, Schönland SO, Schwab Y, Krämer A. Dittrich T, et al. Among authors: haberbosch i. Cell Rep Methods. 2022 Nov 1;2(11):100322. doi: 10.1016/j.crmeth.2022.100322. eCollection 2022 Nov 21. Cell Rep Methods. 2022. PMID: 36452870 Free PMC article.
Software tools for automated transmission electron microscopy.
Schorb M, Haberbosch I, Hagen WJH, Schwab Y, Mastronarde DN. Schorb M, et al. Among authors: haberbosch i. Nat Methods. 2019 Jun;16(6):471-477. doi: 10.1038/s41592-019-0396-9. Epub 2019 May 13. Nat Methods. 2019. PMID: 31086343 Free PMC article. Review.
BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials.
Liebers N, Roider T, Bohn JP, Haberbosch I, Pircher A, Ferstl B, Ebnöther M, Wendtner CM, Dearden C, Follows GA, Ho AD, Müller-Tidow C, Dreger P, Troussard X, Zenz T, Dietrich S. Liebers N, et al. Among authors: haberbosch i. Leukemia. 2020 May;34(5):1454-1457. doi: 10.1038/s41375-019-0646-y. Epub 2019 Nov 18. Leukemia. 2020. PMID: 31740808 No abstract available.
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M, Schäkel U, Djuka Fokou C, Krisam J, Stermann J, Kriegsmann K, Haberbosch I, Novotny JP, Weber S, Vehreschild M, Bornhäuser M, Bullinger L, Schmitt M, Liebregts T, Dreger P, Lorenz HM, Plaszczyca A, Bartenschlager R, Müller B, Kräusslich HG, Halama N, Jäger D, Schlenk RF, Leo A, Meuer S, Weigand MA, Motsch J, Merle U, Denkinger CM, Müller-Tidow C. Janssen M, et al. Among authors: haberbosch i. Trials. 2020 Oct 6;21(1):828. doi: 10.1186/s13063-020-04735-y. Trials. 2020. PMID: 33023671 Free PMC article.
PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.
Mian AA, Rafiei A, Haberbosch I, Zeifman A, Titov I, Stroylov V, Metodieva A, Stroganov O, Novikov F, Brill B, Chilov G, Hoelzer D, Ottmann OG, Ruthardt M. Mian AA, et al. Among authors: haberbosch i. Leukemia. 2015 May;29(5):1104-14. doi: 10.1038/leu.2014.326. Epub 2014 Nov 14. Leukemia. 2015. PMID: 25394714
Loss of the selective autophagy receptor p62 impairs murine myeloid leukemia progression and mitophagy.
Nguyen TD, Shaid S, Vakhrusheva O, Koschade SE, Klann K, Thölken M, Baker F, Zhang J, Oellerich T, Sürün D, Derlet A, Haberbosch I, Eimer S, Osiewacz HD, Behrends C, Münch C, Dikic I, Brandts CH. Nguyen TD, et al. Among authors: haberbosch i. Blood. 2019 Jan 10;133(2):168-179. doi: 10.1182/blood-2018-02-833475. Epub 2018 Nov 29. Blood. 2019. PMID: 30498063 Free article.
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K.
Mian AA, Haberbosch I, Khamaisie H, Agbarya A, Pietsch L, Eshel E, Najib D, Chiriches C, Ottmann OG, Hantschel O, Biondi RM, Ruthardt M, Mahajna J. Mian AA, et al. Among authors: haberbosch i. Ann Hematol. 2021 Aug;100(8):2023-2029. doi: 10.1007/s00277-020-04357-z. Epub 2021 Jun 10. Ann Hematol. 2021. PMID: 34110462 Free PMC article.
BCR: a new target in resistance mediated by BCR/ABL-315I?
Haberbosch I, Rafiei A, Oancea C, Ottmann GO, Ruthardt M, Mian AA. Haberbosch I, et al. Genes Cancer. 2016 Jan;7(1-2):36-46. doi: 10.18632/genesandcancer.93. Genes Cancer. 2016. PMID: 27014420 Free PMC article.